TTK Healthcare Ltd

TTK Healthcare Ltd maintains a strong liquidity position with a current ratio of 5.35, indicating a robust ability to meet short-term obligations. The company's cash and equivalents amount to INR 7.75 billion, significantly exceeding its total liabilities of INR 2.05 billion, and its long-term debt is minimal at INR 228.11 million. The liquidity risk is assessed as low, supported by the absence of immediate filing-based liquidity flags.

Profitability metrics show a return on equity (ROE) of 1.83% and a return on assets (ROA) of 1.51%, which are below the industry median for pharmaceutical companies. The net income of INR 182.72 million is derived from a gross profit of INR 970.71 million, with operating income at INR 90.98 million. These figures suggest a relatively low margin structure compared to industry peers.

The company's revenue is concentrated in its core segments, with diagnostics, medical devices, and hospital services forming the primary revenue streams. No specific geographic breakdown is provided, but the company operates primarily in India. The lack of detailed geographic exposure data limits the assessment of regional concentration risk.

TTK Healthcare Ltd's growth trajectory is modest, with no significant revenue growth or decline reported in the latest financial period. The company's capital expenditure of INR 103.83 million reflects ongoing investment in infrastructure and operations. However, the operating cash flow is negative at INR 49.43 million, indicating potential challenges in generating cash from operations.

Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.02 suggests a conservative capital structure. There is no indication of near-term dilution pressure, and the dilution risk is assessed as low.

Recent events include the latest financial filing, which provides updated financial metrics and operational performance. No significant regulatory or legal events were reported in the latest filings, and the company's risk assessment remains stable.

TTK Healthcare Limited (TTKH.NS) is currently undergoing its first formal analysis, meaning there is no prior baseline to compute material changes or identify specific shifts in performance metrics. Consequently, no significant events, rating adjustments, or holder changes have been recorded for the company at this time. The company’s profile indicates a minimal presence in terms of public scrutiny and institutional tracking. TTK Healthcare Limited has only one listed officer and zero analyst coverage, suggesting a lack of active research interest from the financial community. Furthermore, the stock is not included in any major indices, and there are no identified top holders. This absence of index membership and prominent shareholder data points to a low-profile status within the broader market landscape. Recent monitoring data from late June through mid-July 2026 shows zero daily dispatches and null sentiment readings. This complete lack of news flow or market commentary reinforces the current state of inactivity and limited visibility for TTK Healthcare Limited.

Revenue grew at a 13.9% CAGR over four years, demonstrating consistent top-line expansion for the healthcare company.

Net income surged 29.9% year-over-year to INR 816.6 million, highlighting significant recent profitability improvements.

The company maintains a low debt-to-equity ratio of 0.02, indicating a conservative capital structure with minimal leverage.

Free cash flow increased 22.6% year-over-year to INR 630.2 million, supporting strong liquidity generation capabilities.

Operating income declined 15.0% year-over-year, signaling weakening core operational profitability despite revenue growth.

Operating margin of 5.0% falls below the pharmaceutical cohort median of 5.5%, reflecting competitive pricing pressures.

Cash conversion ratio of -0.27 places the company in the bottom quartile of its peer cohort.

Return on invested capital of 0.9% is significantly low, suggesting limited value creation from deployed capital.

Revenue INR 7.53B, +3,8% YoY; Operating income +30,1% YoY.

• ▍Revenue INR 7.53B, +3,8% YoY
• ▍Operating income +30,1% YoY
• ▍Net income −90,2% YoY
• ▍Free cash flow +62,4% YoY
• ▍Net margin 8.3%

Revenue INR 7.25B, +21,0% YoY; Operating income +101,5% YoY.

• ▍Revenue INR 7.25B, +21,0% YoY
• ▍Operating income +101,5% YoY
• ▍Net income +1 438,2% YoY
• ▍Free cash flow +85,0% YoY
• ▍Net margin 88.2%

Revenue INR 5.99B, +25,9% YoY; Operating income +44,4% YoY.

• ▍Revenue INR 5.99B, +25,9% YoY
• ▍Operating income +44,4% YoY
• ▍Net income −10,4% YoY
• ▍Free cash flow −61,6% YoY
• ▍Net margin 6.9%

Revenue INR 4.76B; Operating income INR 64.2M.

• ▍Revenue INR 4.76B
• ▍Operating income INR 64.2M
• ▍Net margin 9.8%